This is a working overview of human growth hormone, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-11 and is reviewed periodically as new material appears.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
== Drug combination == Some ingredients such as caffeine, creatine and β-alanine are found in nearly all pre-workout blends, but each branded product is a "proprietary blend" with an average of 18 different ingredients, the exact composition and proportions of which can vary widely between different products. Additionally legal psychoactive substances occasionally used in these proprietary blends that are typically legal include 5-HTP, tyrosine, and yohimbine. Although these products are not banned, the Food and Drug Administration warns consumers to be cautious when consuming pre-workout. Benzodiazepines can cause death when mixed with other CNS depressants such as opioids, alcohol, or barbiturates. Alcohol and cocaine (for example coca wine) increase cardiovascular toxicity. Opioids or cocaine taken with ecstasy or amphetamines also result in additional acute toxicity.
== Premise == Wealthy retired lawyer Madeline Kingston vows to get justice for the death of her daughter Ellie in the opioid epidemic. Using the persona of impoverished widow Madeline "Matty" Matlock, Kingston obtains a position at the law firm she believes hid evidence that could have saved her daughter's life. While using her formidable intellect and expertise of the law to assist the firm, she begins slowly digging her way to the truth. Within the universe of this series, the original Matlock series aired as it did in the real world, and Ellie's love of the series inspires Madeline's alias.
=== Jackie Harris === Marjorie Jacqueline "Jackie" Harris Goldufski is played by Laurie Metcalf. Jackie is Roseanne's younger sister by three years. She is a neurotic but a loving, devoted aunt to her nieces and nephews, and later mother to Andy. Jackie is an intelligent, warm, highly sensitive underachiever with chronic low self-esteem. Roseanne seems to be in charge of Jackie's life, which frequently causes conflict between the two sisters; however, Jackie sometimes enjoys having Roseanne mother her, especially when she feels vulnerable. Like Roseanne, Jackie's relationship with their mother is strained, chafing under Bev's constant criticism and disapproval of her life choices. She is closer to her father, but as his past abusive behavior is revealed in later seasons, Jackie is shown as having coped by using selective denial or justifying his behavior. Jackie's character becomes more animated and colorful as the series progresses. Jackie holds numerous jobs: working in the Wellman Plastics factory for several years until the walkout, then becoming a police officer until being injured on the job, then is a truck driver before finally opening the Lanford Lunch Box with Roseanne and Nancy, and also mother Bev as a fourth partner. In Season 10, Jackie is now a life coach. In The Conners, Jackie, along with Becky, revives the old Lanford Lunch Box when the previous restaurant occupying the space closes, then struggles to keep it afloat during the COVID pandemic, showing her adaptability and perseverance. Jackie often comes up with off-the-wall ideas, but many actually work.
Sources: en.wikipedia.org
Gastric acid production is regulated by both the autonomic nervous system and several hormones. The parasympathetic nervous system, via the vagus nerve, and the hormone gastrin stimulate the parietal cell to produce gastric acid, both directly acting on parietal cells and indirectly, through the stimulation of the secretion of the hormone histamine from enterochromaffin-like cells (ECLs). Vasoactive intestinal peptide, cholecystokinin, and secretin all inhibit production. The production of gastric acid in the stomach is tightly regulated by positive regulators and negative feedback mechanisms. Four types of cells are involved in this process: parietal cells, G cells, D cells and enterochromaffin-like cells. Beside this, the endings of the vagus nerve (CN X) and the intramural nervous plexus in the digestive tract influence the secretion significantly. Nerve endings in the stomach secrete two stimulatory neurotransmitters: acetylcholine and gastrin-releasing peptide. Their action is both direct on parietal cells and mediated through the secretion of gastrin from G cells and histamine from enterochromaffin-like cells. Gastrin acts on parietal cells directly and indirectly too, by stimulating the release of histamine. The release of histamine is the most important positive regulation mechanism of the secretion of gastric acid in the stomach. Its release is stimulated by gastrin and acetylcholine and inhibited by somatostatin.
== Possible problems == The maximum pressure rating of a metering pump is actually the top of the discharge pressure range the pump is guaranteed to pump against at a reasonably controllable flow rate. The pump itself is a pressurizing device often capable of exceeding its pressure rating, although not guaranteed to. For this reason, if there is any stop valve downstream of the pump, a pressure relief valve should be placed in between to prevent overpressuring of the tubing or piping line in case the stop valve is inadvertently shut while the pump is running. The relief valve setting should be below the maximum pressure rating that the piping, tubing, or any other components there could withstand. Liquids are only very slightly compressible. This property of liquids lets metering pumps discharge liquids at high pressure. Since a liquid can be only slightly compressed during a discharge stroke, it is forced out of the pump head. Gases are much more compressible. Metering pumps are not good at pumping gases. Sometimes, a metering or similar pump has to be primed before operation, i. e. the pump head filled with the liquid to be pumped. When gas bubbles enter a pump head, the compression motion compresses the gas but has a hard time forcing it out of the pump head. The pump may stop pumping liquid with gas bubbles in the pump head even though mechanically the pump is going through the motions, repeatedly compressing and decompressing the bubbles. To prevent this type of "vapor lock", chromatography solvents are often degassed before pumping.
Embalming chemicals are a variety of preservatives, sanitizers, disinfectant agents, and additives used in modern embalming to temporarily delay decomposition and restore a natural appearance for viewing a body after death. A mixture of these chemicals is known as embalming solution, and is used to preserve deceased individuals, sometimes only until the funeral, other times indefinitely. Typical embalming solution contains a mixture of formaldehyde, glutaraldehyde, methanol, humectants and wetting agents, and other solvents that can be used. The formaldehyde content generally ranges from 5–35%, and the methanol content may range from 9–56%. Environmentalists sometimes have concerns about embalming because of the harmful chemicals involved and their potential interactions with the environment. Recently, more eco-friendly embalming methods have become available, including formaldehyde-free mixtures of chemicals.
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.